You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Ant-angiogenic therapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Predict Efficacy of Anti-angiogenic Therapy in Ovarian Cancer

Active, not recruiting
  • Epithelial Ovarian Cancer
  • liquid biopsy
  • Aviano, Italy
    Centro di Riferimento Oncologico (CRO), IRCCS
May 16, 2023

Brain Tumors by Advanced MRI

Completed
  • Glioblastoma
  • Avastin
  • +5 more
  • Boston, Massachusetts
    Massachusetts general Hospital
Apr 6, 2022

Ocular Blood Flow in Colorectal Cancer Patients

Terminated
  • Metastatic Colorectal Cancer
    • Vienna, Austria
      Medical University of Vienna
    Apr 23, 2022

    Hereditary Hemorrhagic Telangiectasia Trial in Toronto (Topical timolol maleate, saline drops)

    Completed
    • Hereditary Hemorrhagic Telangiectasia
    • Topical timolol maleate
    • placebo saline drops
    • Toronto, Ontario, Canada
      St. Michael's Hospital
    Nov 19, 2021

    Metastatic Renal Cell Carcinoma Trial in Cleveland (Nivolumab, Ipilimumab)

    Active, not recruiting
    • Metastatic Renal Cell Carcinoma
    • Cleveland, Ohio
      Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Ca
    Jan 25, 2023

    18F-fluorodeoxyglucose Positron Emission Tomography and Brain

    Recruiting
    • Glioblastoma
    • FDG PET
    • +2 more
    • Nîmes, France
      CHU de Nimes
    Oct 15, 2021

    Glioma, Neuroectodermal Tumors, Primitive, Wilms Tumor Trial in Saint Louis (Metronomic Cyclophosphamide, Thalidomide)

    Recruiting
    • Glioma
    • +6 more
    • Saint Louis, Missouri
      Washington University School of Medicine
    Sep 22, 2021

    NSCLC Trial in Changsha (envafolimab)

    Enrolling by invitation
    • Non-small Cell Lung Cancer
    • Changsha, Hunan, China
      the second Xiangya hospital
    May 1, 2022

    Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCC

    Recruiting
    • Hepatocellular Carcinoma
    • Anti-angiogenic agents plus anti-PD-1/PD-L1 antibodies
    • Shanghai, Shanghai, China
      Zhongshan Hospital, Fudan University
    Jul 23, 2021

    Colorectal Cancer Trial in Dijon (OCT- Angiographie)

    Recruiting
    • Colorectal Cancer
    • OCT- Angiographie
    • Dijon, France
    • +1 more
    Jul 2, 2021

    Rare Tumor, Refractory Tumor Trial in Shanghai (Gefitinib, Erlotinib, Afatinib)

    Recruiting
    • Rare Tumor
    • Refractory Tumor
    • Shanghai, Shanghai, China
      Shanghai Changzheng Hospital
    Feb 16, 2022

    Non Small Cell Lung Cancer Trial in Philadelphia (Nivolumab, Ramucirumab)

    Recruiting
    • Non Small Cell Lung Cancer
    • Philadelphia, Pennsylvania
      Fox Chase Cancer Center
    Apr 6, 2022

    Cancer of Prostate Trial in Belgium (Apalutamide, Leuprorelin Acetate 45Mg Powder for Injection Suspension Vial, Goserelin

    Recruiting
    • Cancer of Prostate
    • Aalst, Belgium
    • +8 more
    Aug 4, 2021

    Soluble Mediators, Cytokines, and Circulating Angiogenic Factors

    Active, not recruiting
    • Non-small Cell Lung Cancer
      • Elche, Alicante, Spain
      • +24 more
      Nov 8, 2022

      Seizures, Epilepsy, Seizure Disorder Trial in Durham (ANT recording and stimulation)

      Not yet recruiting
      • Seizures
      • +2 more
      • ANT recording and stimulation
      • Durham, North Carolina
        Duke University Health System
      Mar 31, 2022

      Surufatinib Plus Sintilimab Combined With Chemotherapy in

      Recruiting
      • Gastric Neuroendocrine Carcinoma
      • Tianjin, Tianjin, China
        Tianjin Medical University Cancer Institute and Hospital
      Oct 22, 2023

      Wounds Trial (VAC® Therapy System)

      Withdrawn
      • Wounds
      • VAC® Therapy System
      • (no location specified)
      Jul 29, 2022

      PFS, OS Trial in Qingdao (PD-1 inhibitor, Bevacizumab, Carboplatin, Cisplatin, Pemtrexed)

      Recruiting
      • PFS
      • OS
      • PD-1 inhibitor, Bevacizumab, Carboplatin, Cisplatin, Pemtrexed
      • Qingdao, Shandong, China
        Qingdao central Hospital
      Feb 23, 2022

      Atrial Fibrillation (AF), Stroke Trial in Worldwide (Abelacimab, Rivaroxaban)

      Active, not recruiting
      • Atrial Fibrillation (AF)
      • Stroke
      • Huntsville, Alabama
      • +93 more
      Jan 25, 2023

      Anterior Wall Myocardial Infarction Trial in Canada (Plasma-Lyte A and 25% Autologous Plasma, Autologous EPCs, Autologous EPCs

      Active, not recruiting
      • Anterior Wall Myocardial Infarction
      • Plasma-Lyte A and 25% Autologous Plasma
      • +2 more
      • Ottawa, Ontario, Canada
      • +3 more
      Dec 1, 2020

      Breast Cancer Stage IV Trial in Iowa City, New Delhi, Chandigarh (Lutetium-177-PEG-avß3-IAC)

      Not yet recruiting
      • Breast Cancer Stage IV
      • Iowa City, Iowa
      • +2 more
      Jun 7, 2022

      Cardiovascular Disorder, Chronic Kidney Disease, Metastatic Renal Cell Carcinoma Trial in United States (Best Practice, Blood

      Recruiting
      • Cardiovascular Disorder
      • +8 more
      • Best Practice
      • +4 more
      • Creve Coeur, Missouri
      • +24 more
      Aug 10, 2022

      Colon Cancer With Metastases to the Liver Trial in Argentina, United States (LC beads loaded with Irinotecan, Oxaliplatin,

      Completed
      Has Results
      • Colon Cancer With Metastases to the Liver
      • LC beads loaded with Irinotecan
      • +4 more
      • Huntsville, Alabama
      • +9 more
      Jun 9, 2021

      Purinergic Signaling and the Postmenopausal Heart

      Recruiting
      • Diastolic Heart Failure
      • Heart Failure With Preserved Ejection Fraction
      • Gender
      • Boston, Massachusetts
        Beth Israel Deaconess Medical Center
      Aug 28, 2023

      Hepatocellular Carcinoma Recurrent Trial in Chongqing (Tislelizumab/Sintilimab+Lenvatinib/Bevacizumab, RFA)

      Recruiting
      • Hepatocellular Carcinoma Recurrent
      • Chongqing, Chongqing, China
        Institute of hepatobiliary surgery,Southwest Hospital
      Mar 11, 2022